These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9642622)

  • 1. Copolymer-1 in the treatment of multiple sclerosis.
    Boyden KM
    J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB
    Neurology; 1995 Jul; 45(7):1268-76. PubMed ID: 7617181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
    Johnson KP
    Mult Scler; 1996 Jul; 1(6):325-6. PubMed ID: 9345409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data.
    Johnson KP
    J Neurol; 1996 Apr; 243(4 Suppl 1):S3-7. PubMed ID: 8965118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copolymer-1.
    Comi G; Moiola L
    Baillieres Clin Neurol; 1997 Oct; 6(3):495-509. PubMed ID: 10101586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.
    Flechter S; Kott E; Steiner-Birmanns B; Nisipeanu P; Korczyn AD
    Clin Neuropharmacol; 2002; 25(1):11-5. PubMed ID: 11852290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
    Balabanov R; Lisak D; Beaumont T; Lisak RP; Dore-Duffy P
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1196-203. PubMed ID: 11687463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group.
    Liu C; Blumhardt LD
    J Neurol Sci; 2000 Dec; 181(1-2):33-7. PubMed ID: 11099709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
    Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD
    Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.